R-CHOP protocol clinical trials
How each study uses R-CHOP protocol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the R-CHOP protocol studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Sun Yat-sen University (2) · University Health Network, Toronto (1) · University Hospital Muenster (1) · Huiqiang Huang (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test R-CHOP protocol.
- Nov 2026Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)Phase 2 · Sun Yat-sen University
- Jan 2027Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)Phase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses R-CHOP protocol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)RecruitingPhase 2Sun Yat-sen UniversityNCT06517511Written as R-CHOP ProtocolHow we know
- Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)RecruitingPhase 2Sun Yat-sen UniversityNCT06647940Written as R-CHOP ProtocolHow we know
- Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell LymphomaRecruitingPhase 1/2Huiqiang HuangNCT04058470Written as R-CHOP ProtocolHow we know
- Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCLCompletedPhase 2University Hospital MuensterNCT04263584Written as R-CHOP ChemotherapyHow we know
- Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell LymphomaActive, not recruitingPhase 2University Health Network, TorontoNCT04566887Written as R-CHOP chemotherapyHow we know
Given beside what is tested · 2 — R-CHOP protocol is usual care or a partner of the new treatment
- Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL PatientsRecruitingPhase 1/2Sun Yat-sen UniversityNCT05577364Written as R-CHOP ProtocolHow we know
- Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell LymphomaActive, not recruitingPhase 2University of ChicagoNCT03995147Written as R-CHOP ProtocolHow we know